anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of medicine, and particularly relates to a loxoprofen sodium compound. The structural formula of the loxoprofen sodium compound is as follows: the loxoprofen sodium compound is measured through Cu-K alpha rays, and an X-ray powder diffraction spectrogram is obtained and shown as a figure 1. The loxoprofen sodium compound has low possibility of moisture absorption and has very excellent liquidity, so that the accuracy of subpackage is improved, and the loxoprofen sodium compound and other ingredients can be easily and uniformly mixed. The invention further provides a preparation method of the loxoprofen sodium compound and a pharmaceutical composition containing the loxoprofen sodium compound. The pharmaceutical composition can be prepared into a granule, a tablet or a capsule, preferably the capsule. Finally, the invention further provides a preparation method of the pharmaceutical composition.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to anesthesiology, and may be used as an anesthesia care when performing eye removal surgery. To do this, venipuncture is performed 30 minutes before the operation and 500 mg of tranexane and 8 mg of xefocam are administered. Next, blockade of the pterygium fossa is performed with a mixture of naropine 0.75 % (4 ml) and dexamethasone (3 mg). Needle is inserted directly below the lower edge of the zygomatic arch and advanced through the notch of the branch of the lower jaw toward the base of the external plate of the pterygoid process. Intraoperative premedication with sibazone is carried out, introductory anesthesia is carried out with diprivane against the background of mask inhalation with sevoflurane. Anesthesia is maintained by sevoflurane at a dose of 2.2–2.5 % by volume, with spontaneous respiration preserved. Before the end of the operation, paracetamol is administered intravenously at a dose of 15 mg/kg.EFFECT: method provides adequate and controlled anesthesia, as well as a “smooth” anesthesia recovery of the patient due to the original combination of the mode of administration of various drugs at various stages of surgical intervention.1 cl, 2 ex
Aside from enabling voluntary control over paralyzed muscles, a key effect of spinal cord stimulation is the alleviation of spasticity. Dysfunction of spinal inhibitory circuits is considered a major cause of spasticity. These circuits are contacted by Ia muscle spindle afferents, which are also the primary targets of transcutaneous lumbar spinal cord stimulation (TSCS). We hypothesize that TSCS controls spasticity by transiently strengthening spinal inhibitory circuit function through their Ia-mediated activation. We show that 30 min of antispasticity TSCS improves activity in post- and presynaptic inhibitory circuits beyond the intervention in ten individuals with traumatic spinal cord injury to normative levels established in 20 neurologically intact individuals. These changes in circuit function correlate with improvements in muscle hypertonia, spasms, and clonus. Our study opens the black box of the carryover effects of antispasticity TSCS and underpins a causal role of deficient post- and presynaptic inhibitory circuits in spinal spasticity.
FIELD: medicine. SUBSTANCE: one should carry out extraction of reduced larch wood with aqueous solution of organic solvent, solvent's distillation and recrystallization of aqueous-phase precipitated residue. After recrystallization obtained product should be dissolved in aqueous solution of ethanol at heating, then obtained solution should be cooled up to 10 C, not higher. Precipitated residue should be filtered followed by repeated recrystallization in the mixture of acetonitril and aqueous solution of acetic acid. EFFECT: improved ecological value. 2 cl, 1 ex
The effectiveness of Depakote for the treatment of acute mania was demonstrated in two 3-week, placebo controlled, parallel group studies. 

(1) Study 1: The first study enrolled adult patients who met DSM-III-R criteria for bipolar disorder and who were hospitalized for acute mania. In addition, they had a history of failing to respond to or not tolerating previous lithium carbonate treatment. Depakote was initiated at a dose of 250 mg tid and adjusted to achieve serum valproate concentrations in a range of 50-100 mcg/mL by day 7. Mean Depakote doses for completers in this study were 1,118, 1,525, and 2,402 mg/day at Days 7, 14, and 21, respectively. Patients were assessed on the Young Mania Rating Scale (YMRS; score ranges from 0-60), an augmented Brief Psychiatric Rating Scale (BPRS-A), and the Global Assessment Scale (GAS). Baseline scores and change from baseline in the Week 3 endpoint (last-observation-carry-forward) analysis were as follows: 

Depakote was statistically significantly superior to placebo on all three measures of outcome. 

(2) Study 2: The second study enrolled adult patients who met Research Diagnostic Criteria for manic disorder and who were hospitalized for acute mania. Depakote was initiated at a dose of 250 mg tid and adjusted within a dose range of 750-2,500 mg/day to achieve serum valproate concentrations in a range of 40-150 mcg/mL. Mean Depakote doses for completers in this study were 1,116, 1,683, and 2,006 mg/day at Days 7, 14, and 21, respectively. Study 2 also included a lithium group for which lithium doses for completers were 1,312, 1,869, and 1,984 mg/day at Days 7, 14, and 21, respectively. Patients were assessed on the Manic Rating Scale (MRS; score ranges from 11-63), and the primary outcome measures were the total MRS score, and scores for two subscales of the MRS, i.e., the Manic Syndrome Scale (MSS) and the Behavior and Ideation Scale (BIS). Baseline scores and change from baseline in the Week 3 endpoint (last-observation-carry-forward) analysis were as follows: 

Depakote was statistically significantly superior to placebo on all three measures of outcome. An exploratory analysis for age and gender effects on outcome did not suggest any differential responsiveness on the basis of age or gender. 

A comparison of the percentage of patients showing ≥ 30% reduction in the symptom score from baseline in each treatment group, separated by study, is shown in Figure 1. 

Figure 1

* p < 0.05 

PBO = placebo, DVPX = Depakote
Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
Chronic lymphocytic leukemia (CLL) is the most common of the chronic lymphoid leukemias, comprising 30% of all adult leukemias. The majority of CLL patients are of advanced age. Currently, immunochemotherapy with Rituximab, Fludarabine and Cyclophosphamide (RFC) is the standard of care in previously untreated patients with CLL requiring treatment. The combination of Pentostatin and Cyclophosphamide has generated excellent clinical response rates in pretreated B-CLL patients. Early data on the use of Ofatumumab as a single agent in Fludarabine-refractory CLL patients have been reported. Given the reported efficacy of chemo-immunotherapy combinations in CLL and the promising activity and toxicity profile of Pentostatin combinations, we designed a trial of Pentostatin, Cyclophosphamide, and Ofatumumab for previously untreated older patients with CLL. The aim is improving efficacy, in Rituximab resistant CLL, and toxicity considering the good profile of tolerability showed using Ofatumumab as single agent.
All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period, the investigator will stimulate the auricular branch of the vagus nerve. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
AIMS: Worsening heart failure (WHF) events occurring in non-inpatient settings are becoming increasingly recognized, with implications for prognostication. We evaluate the performance of a natural language processing (NLP)-based approach compared with traditional diagnostic coding for non-inpatient clinical encounters and left ventricular ejection fraction (LVEF).
METHODS AND RESULTS: We compared characteristics for encounters that did vs. did not meet WHF criteria, stratified by care setting [i.e. emergency department (ED) and observation stay]. Overall, 8407 (22%) encounters met NLP-based criteria for WHF (3909 ED visits and 4498 observation stays). The use of an NLP-derived definition adjudicated 3983 (12%) of non-primary HF diagnoses as meeting consensus definitions for WHF. The most common diagnosis indicated in these encounters was dyspnoea. Results were primarily driven by observation stays, in which 2205 (23%) encounters with a secondary HF diagnosis met the WHF definition by NLP.
CONCLUSIONS: The use of standard claims-based adjudication for primary diagnosis in the non-inpatient setting may lead to misclassification of WHF events in the ED and overestimate observation stays. Primary diagnoses alone may underestimate the burden of WHF in non-hospitalized settings.
Following anesthesia and the surgical procedure, the needle will be advanced at an angle of 30-40° under ultrasonography guidance in the paramedian sagittal plane, lateral to the T5 spinos process, and entered into the location of the superior costotransverse ligament. The location of the serum and needle will be confirmed by hydrodissection without local anesthesia. Once the location of the needle is confirmed, a mixture of 20 ml of 0.25% bupivacaine will be applied.
Rattusin, an α-defensin-related antimicrobial peptide isolated from the small intestine of rats, has been previously characterized through NMR spectroscopy to elucidate its three-dimensional structure, revealing a C2 homodimeric scaffold stabilized by five disulfide bonds. This study aimed to identify the functional region of rattusin by designing and synthesizing various short analogs, subsequently leading to the development of novel peptide-based antibiotics. The analogs, designated as F1, F2, F3, and F4, were constructed based on the three-dimensional configuration of rattusin, among which F2 is the shortest peptide and exhibited superior antimicrobial efficacy compared to the wild-type peptide. The central cysteine residue of F2 prompted an investigation into its potential to form a dimer at neutral pH, which is critical for its antimicrobial function. This activity was abolished upon the substitution of the cysteine residue with serine, indicating the necessity of dimerization for antimicrobial action. Further, we synthesized β-hairpin-like analogs, both parallel and antiparallel, based on the dimeric structure of F2, which maintained comparable antimicrobial potency. In contrast to rattusin, which acts by disrupting bacterial membranes, the F2 dimer binds directly to DNA, as evidenced by fluorescence assays and DNA retardation experiments. Importantly, F2 exhibited negligible cytotoxicity up to 515 μg/mL, assessed via hemolysis and MTT assays, underscoring its potential as a lead compound for novel peptide-based antibiotic development.
Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
PURPOSE:To provide the titled preparation containing secretin, having specific pH and osmotic pressure ratio as an aqueous solution, and useful as a remedy for the diseases of the pancreas and the gallbladder. CONSTITUTION:The objective secretin preparation for transnasal administration is obtained by compounding a secretin (e.g. swine-originated natural secretin, synthetic secretin, etc.) in an amount of 0.0004-0.04W/V% and adjusting the pH of the aqueous solution to 2-5 and the osmotic pressure ratio to 1-5. A citrate- phosphate buffer solution may be added to the preparation to adjust or maintain the pH to 2-5. The transnasal absorption can be promoted by adjusting the pH to 2-5, and the cumulative amount of the increase in the external secretion from the pancreas can be increased. The adjustment of the osmotic pressure to 1-5 can be achieved by adding a proper amount of NaCl. A similar effect as above can be attained thereby.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

My Way was studied in a randomized, double-blinded multicenter clinical trial. In this study, all women who had received at least one dose of study medication were included in the safety analysis: 1,379 women in the My Way group, and 1,377 women in the Plan B group (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). The mean age of women given My Way was 27 years. The racial demographic of those enrolled was 54% Chinese, 12% Other Asian or Black, and 34% were Caucasian in each treatment group. 1.6% of women in the My Way group and 1.4% in Plan B group were lost to follow-up.

The most common adverse events (>10%) in the clinical trial for women receiving My Way included heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal pain (13.3%), fatigue (13.3%), and headache (10.3%). Table 1 lists those adverse events that were reported in > 4% of My Way users.
The invention relates to a liquid preparation for veterinary medicine, said preparation containing meloxicam as a first active ingredient, penethamate hydroiodide as a second active ingredient, and at least one solvent. The invention also relates to a method for the production of said preparation, and to the use of the same. According to the invention, a mixture of meloxicam and penethamate hydroiodide is first prepared. The treatment of mammals with this mixture was not possible until now, as the required stability of use could not be achieved. The inventive preparation, however, displays a surprising stability. It can be used as a combination preparation both for the treatment of mastitis and respiratory infections.
The invention discloses an anti-human PD1 nano antibody and a coding sequence, a preparation method and application thereof, and the VHH chain of the anti-PD 1 nano antibody has an amino acid sequence shown in SEQ ID NO. 2 or SEQ ID NO. 11. Compared with the prior art, the invention has the following advantages: (1) the anti-PD 1 nano antibody has high specificity, high affinity and high detection sensitivity; (2) the antibody can be efficiently expressed in escherichia coli, so that a foundation is provided for the mass production of subsequent immunological reagents and tumor pharmaceutical compositions. The invention discloses an anti-human PD1 nano antibody and a coding sequence, a preparation method and application thereof, and the VHH chain of the anti-PD 1 nano antibody has an amino acid sequence shown in SEQ ID NO. 2 or SEQ ID NO. 11. Compared with the prior art, the invention has the following advantages: (1) the anti-PD 1 nano antibody has high specificity, high affinity and high detection sensitivity; (2) the antibody can be efficiently expressed in escherichia coli, so that a foundation is provided for the mass production of subsequent immunological reagents and tumor pharmaceutical compositions.
The present invention relates to a medical waste treatment method for collecting and incinerating medical waste in real-time in the order, in which the medical waste is loaded, after loading using the Internet of Things. The medical waste treatment method for collecting and incinerating medical waste in real-time in the order, in which the medical waste is loaded, after loading using the Internet of things is configured to sequentially conduct a loading process (S100), a transportation process (S200), an incineration process (S300), and a charging process (S400) by using a vehicle personal computer (PC) of a vehicle that collects and transports a collection trash bin inside a medical waste bin recognizing a discharging person and a collector, an incineration PC of an incineration plant, and the Internet communication network. In the loading process (S100), the collection trash bin, the vehicle PC, and the incineration PC are managed in real-time using the Internet of Things, data is encrypted and processed through a blockchain server, a compression means is used to compress medical waste in the collection trash bin when the volume of the medical waste in the collection trash bin is high compared to its weight, and the blockchain server (240) linked with a main server (230) is used to store a private key in an electronic wallet (250) after loading. In the transportation process (S200), the main server (230) recognizes the completion of the loading process (S100), and collection trash bins are transported in order of sorting through location recognition after loading. In the incineration process (S300), the waste is weighted at the incineration plant following the transportation process (S200), and the weight of the waste and incineration expenses are charged to the main server (230). In the charging process (S400), the main server (230) adds transport expenses and management expenses to the incineration expenses and charges the discharging person for the above expenses. According to the present invention, the medical waste can be efficiently collected.
The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
BACKGROUND: Augmentation mastopexy focuses on restoring the youthful appearance of the female breast. Despite those benefits, there is large scarring to be considered, and the reduction of this side effect is the main goal to enhance the aesthetic result. This article aims to describe a variation of the L-shaped mastopexy technique without complex marking and performed in planes, which improves long-term results for patients undergoing this approach.
METHODS: This is a retrospective, observational study, based on a series of cases conducted by the author. The preoperative appointment and the surgical technique are described and divided into steps according to their components: cutaneous, glandular tissue, and muscular.
RESULTS: Between January of 2016 and July of 2021, 632 women underwent surgery. The mean age was 38 years (range, 18 to 71 years). The mean volume of implants was 285 cc (range, 175 to 550 cc). All the implants used were round with a nanotextured surface. The mean amount of tissue resected from each breast was 117 g (range, 5 to 550 g). Follow-ups ranged from 12 to 84 months, and photographic documentation was performed from 30 days after surgery. Complications totaled 19.30% and were divided into minor [treated with expectant treatment, noninvasive, or with the possibility of correction with local anesthesia (10.44%)] and major [in which it was necessary to return to the operating room (8.86%)].
CONCLUSIONS: Multiplane L-scar mastopexy is a versatile and safe technique with predictable results, which allows the systematic treatment of the most diverse breast types, with complications similar to other already described and solidified techniques.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
A system and method of mapping a patient pathway within a medical environment wherein the method is AI-assisted. The medical environment may relate to an HIV service. Disclosed are a set of interrelated computer programs. A first application is for clinical decision-making, risk prediction, personalised treatment strategies, management of co-morbidity, drug interactions, resistances, and mutation. A second program simulates a pathway within an HIV service and may compare current practices against potential scenarios to aid in decision making. A third program provides personalised medical information to patients. A fourth program monitors patient interaction with the third program to improve the provision of services. A fifth program provides for patient recruitment, and a sixth program analyses electronic medical records.
PURPOSE: Reoperative partial nephrectomy (RePN) offers several advantages for the treatment of recurrent, multifocal renal masses. RePN has been previously demonstrated to be technically feasible and delay the need for renal replacement therapy. However, there is still inherent complexity and known risks to reoperative nephrectomy. We studied the largest population of RePNs to characterize renal functional outcomes and the likelihood of intra- and postoperative complications.
MATERIALS AND METHODS: Query of an institutional surgical registry was conducted. Demographic data, serum creatinine for estimated glomerular filtration rate (eGFR), and protein dipstick results were assessed within 1 week prior to surgery, and postoperative function assessments were studied within a year of surgery. RePN was defined as serial surgical resection of the ipsilateral renal unit.
RESULTS: A total of 1131 partial nephrectomies performed on 663 patients at a single center were retrospectively evaluated. In reoperative cases, median number of operations per renal unit was 2 (range: 2-6). There was a stepwise decline in eGFR with an average decline of 6.1 with each RePN. With each subsequent nephrectomy, surgical duration, estimated blood loss, and incidence of preoperative anemia increased. Postoperative eGFR showed a significant positive association with preoperative eGFR, while negative associations were found with age, number of previous ipsilateral partial nephrectomies, number of tumors, and largest tumor size. High-grade complications were associated with the number of ipsilateral partial nephrectomies, tumor count, and tumor size. Robotic or laparoscopic procedures exhibited a likelihood of grade 3 or greater complications compared to open surgery.
CONCLUSIONS: RePN contributes to renal dysfunction and an increased risk of surgical complications. Intraoperative blood loss and surgical duration increase with subsequent nephrectomy. Such risks are dependent on the number of prior operative interventions on the kidney, suggesting a stepwise progression of surgical morbidity.
Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
The intervention arm will receive education about HIV and heart disease risk via mobile phone text messages for up to 6 months. They will receive the text messages 3-5 times per week. The messages will include information about HIV and risk of heart disease and information about how to reduce heart disease risk. The intervention arm will also receive brief monthly surveys via a digital research platform.